磁共振-超声融合与器官追踪引导下的前列腺癌靶向微波消融:首项2期试验(TMA-HK)最终结果
TMA-HK是首项2期试验,纳入30例低危或中危前列腺癌患者,经会阴在磁共振-超声融合与器官追踪引导下行靶向微波消融。6个月时靶向联合18针系统穿刺活检显示,90.5%(38/42)的治疗区域未检出癌;12个月时野外活检阳性率为40.0%(12/30),仅报告自限性1-2级并发症。
要点
- 30例低危或中危前列腺癌患者共治疗42个区域,6个月时90.5%(38/42)的治疗区域未检出癌。
- 患者层面分析显示10.0%(3/30)出现野内复发,其中2例为分级分组1、1例为分级分组2。
- 12个月时野外活检阳性率为40.0%(12/30),仅报告自限性1级和2级并发症。
核心结论
- TMA治疗前列腺癌可实现有效消融,在长达12个月内获得良好的肿瘤控制。
研究设计与样本
- TMA-HK是首项2期试验(NCT04113811),纳入30例低危或中危前列腺癌患者,经会阴在磁共振-超声融合与器官追踪引导下行靶向微波消融。
主要发现
- 共治疗30例患者的42个区域(7例低危、23例中危),90.5%(38/42)的治疗区域未检出癌。
- 患者层面分析显示野内复发率为10.0%(3/30),其中2例为分级分组1、1例为分级分组2。
- 12个月时野外活检阳性率为40.0%(12/30),其中10例为分级分组1、2例为分级分组2。
- 仅报告自限性1级和2级并发症;3例患者(10.0%)报告新发无法实现插入式性交。
局限性
- 原文指出需要在更大患者群体和更长随访中进一步研究以确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted microwave ablation (TMA) is a novel focal therapy modality for prostate cancer (PC). TMA-HK is the first phase 2 trial investigating the efficacy and functional outcomes of transperineal TMA (NCT04113811) in 30 men with low- or intermediate-risk PC. TMA was performed transperineally with magnetic resonance imaging (MRI)-ultrasound fusion guidance and organ-based tracking. All participants underwent prostate MRI at 6 mo after TMA, followed by targeted and 18-core systematic prostate biopsy. The primary outcome was cancer detection on biopsy in each ablated area at 6 mo. Secondary outcomes included per-patient analysis of positive biopsy results, complications, and functional outcomes at 12 mo. A total of 42 areas were treated in 30 patients (seven low-risk and 23 intermediate-risk PC), with no cancer detected in 90.5% (38/42) of the treated areas. Per-patient analysis revealed in-field recurrence in 10.0% (three of 30) of patients, of whom two had grade group 1 and one had grade group 2 disease. At 12 mo, out-of-field biopsies were positive in 40.0% (12/30) of the patients (ten grade group 1, two grade group 2 disease). Only self-limiting grade 1 and 2 complications were reported. Three patients (10.0%) reported de novo failure to achieve penetrative sexual intercourse. The results demonstrate that TMA for PC resulted in effective ablation, with good cancer control up to 12 mo. PATIENT SUMMARY: We performed the first efficacy trial of targeted microwave treatment for prostate cancer in 30 patients with low- or intermediate-risk disease. Our results show that this treatment achieved excellent local control of the cancer up to 12 months, with a low rate of complications. More research in larger patient groups and over longer follow-up is needed to confirm these findings.
引用
- Chiu PK, Liu AQ, Yee CH, et al. Targeted Microwave Ablation for Prostate Cancer Under Magnetic Resonance Imaging-Ultrasound Fusion and Organ-based Tracking: Final Results from the First Phase 2 Trial (TMA-HK). Eur Urol Oncol. 2024. PMID: 39689992. doi:10.1016/j.euo.2024.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。